Clinical analysis of fulminant type 1 diabetes in China and comparison with a nationwide survey in Japan

Liu, Lan; Mao, Jiping; Lu, Zeyuan; Yan, Xiao‐Jie; Ye, Yiyi; Jiang, Fengxiu

doi:10.1016/j.dsx.2012.08.007

Cited by 5 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These ndings are quite surprising contrast with Imagawa's study, which showed only 4.8% (7/138) patients had GAD-Ab detected in a national survey in 2003 [12]. However, they are consistent with Zheng or Liu's studies that detected GAD-Ab in 35% and 30%, respectively, of FT1DM patients [2,5].…”

Section: Discussioncontrasting

confidence: 57%

“…Lan Liu et al showed that HbA1c was elevated after 6 months of follow-up of FT1DM patients and C-P0 and C-P120 were not signi cantly different from onset of the disease [5]. 5 FT1DM patients were followed up by Lu Zeyuan et al for 3-26 months indicated that C-P0 and C-P 120 were extremely poor, and there was no difference with the onset of FT1DM [14].…”

Section: Discussionmentioning

confidence: 99%

“…In the recent years, FT1DM has attracted worldwide attention with the increasing number of cases. There are more reports of FT1DM, especially in East Asia [2][3][4][5][6]. These reports mainly described the clinical characteristics and etiological analysis of FT1DM.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A follow-up study of fulminant type 1 diabetes mellitus

Wang¹,

Liu²,

Li³

et al. 2021

Preprint

View full text Add to dashboard Cite

ObjectivesTo explore the possible mechanisms of glycol-metabolism and islet function in patients with fulminant type 1 diabetes (FT1DM).MethodsA follow-up study was conducted on 13 patients with FT1DM from September 2000 to March 2018. Patient general clinical data were collected and analyzed. The gene sequences of Human leukocyte antigen (HLA)-DRB1, HLA-DQA1 and HLA-DQB1 were analyzed by polymerase chain reaction (PCR).ResultsCompared with baseline, the waist-hip ratio was significantly increased at follow-up (P<0.05). Compared with baseline, HbA1c significantly increased; C-P0 and C-P120 significantly decreased, and the differences were statistically significant (P<0.05). Compared with baseline, White blood cell count (WBC), aspartate aminotransferase (AST), serum potassium (K), creatinine (Cr), glutamyl transpeptidase (GGT), creatine kinase (CK), alkalinity phospholipase (AKP) decreased significantly (P<0.05), while cholesterol (TC) and high-density lipoprotein (HDL) increased significantly (P<0.05). Viral antibody was detected in 13 cases of FT1DM: Coxsackie viral antibody was positive in 2 cases and herpes simplex viral antibody was positive in 3 cases. Gene detection: The higher frequency of HLA-DRB1 allele was DRB1*0301 (88.9%), DRB1*07 (44.4%), and the higher frequency of HLA-DQA1 allele was DQA1*0104 (55.6%), DQA1*0103 (44.4%), and the higher frequencies of HLA-DQB1 allele were DQB1*0201 (50.0%), DQB1*0502 (33.3%), and DQB1*0301 (25.0%).ConclusionsAlthough the β-cell function of FT1DM was progressively irreversibly destroyed with the progression of the disease, metabolic disorders and stress responses were relieved at the later stage. Viral infections (herpes simplex virus, Coxsackie virus), HLA-DQ, DR genes, GAD-Ab and other related antibodies may be involved in the occurrence of FT1DM.

show abstract

Section: Discussioncontrasting

confidence: 57%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A follow-up study of fulminant type 1 diabetes mellitus

Wang¹,

Liu²,

Li³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Cellular and humoral immunity may play an important role in FT1D (29). Viral infection and drug induction may lead to b-cell loss in FT1D by triggering an immune response (32,33). The present results indicated that circRNAs were abnormally expressed in peripheral immune cells in FT1D, and bioinformatics analysis indicated that circRNAs may be involved in the immune response.…”

Section: Discussionmentioning

confidence: 51%

Identification of hsa_circRNA_100632 as a novel molecular biomarker for fulminant type 1 diabetes

Yin

Luo²,

Qiu³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

ObjectiveCircular RNAs (circRNAs) are associated with diabetes, but their role in fulminant type 1 diabetes (FT1D) is unclear. Thus, we characterized the role of circRNAs in FT1D.Research design and methodsCircRNA expression profiles were detected in peripheral blood mononuclear cells (PBMCs) of five FT1D patients and five controls using a circRNA microarray. An independent cohort comprised of 40 FT1D cases, 75 type 1 diabetes (T1D) cases, and 115 controls was used to verify the circRNAs using quantitative real-time polymerase chain reaction (qRT-PCR). Spearman’s correlation analysis and receiver operating characteristic (ROC) curve analysis were performed to determine the clinical diagnostic capability of circRNAs. Bioinformatics was used to identify potential biological functions and circRNA–miRNA–mRNA interactions.ResultsThere were 13 upregulated and 13 downregulated circRNAs in PBMCs of patients with FT1D. Five circRNAs were further verified in a second cohort. Hsa_circRNA_100632 was significantly upregulated in the FT1D and T1D groups. Hsa_circRNA_100632 was differentiated between patients with FT1D and controls [area under the curve (AUC) 0.846; 95% CI 0.776–0.916; P<0.0001] as well as between patients with FT1D and patients with T1D (AUC 0.726; 95% CI 0.633–0.820; P<0.0001). Bioinformatics analysis showed that hsa_circRNA_100632 may be involved in 47 circRNA–miRNA–mRNA signaling pathways associated with diabetes.ConclusionsCircRNAs were aberrantly expressed in PBMCs of patients with FT1D, and hsa_circRNA_100632 may be a diagnostic marker of FT1D.

show abstract

“…The incidence of fT1D was 7.1% in newly diagnosed T1D patients in Korea, and adult (≥18 years) onset accounted for 30.4% . In various studies from China, it was reported that the incidence of fT1D is from 1.5% to 5.45%, which is far lower than the data in nationwide survey in Japan . It has been reported that the prevalence of diabetes mellitus rising among young adults in Asian populations is caused by a complex set of factors, with fT1D possibly being among these factors (Table ).…”

Section: Epidemiologymentioning

confidence: 98%

Recent findings on fulminant type 1 diabetes

Liu

Zeng

Sang

et al. 2017

Diabetes Metabolism Res

Self Cite

View full text Add to dashboard Cite

SummaryFulminant type 1 diabetes (fT1D) is a new subtype of type 1 diabetes proposed by Imagawa in 2000. It is a clinical syndrome characterized by a markedly rapid and almost complete destruction of pancreatic β cells. Metabolic derangement is more severe in this subtype than in autoimmune type 1 diabetes. The incidence of fT1D is associated with HLA DRB1*04:05DQB1*04:01; both innate and acquired immune disorders might contribute to the development of fT1D. The presence of specific innate immune responses to enterovirus infection connected with enhanced adaptive immune pathways responsible for aggressive β cell toxicity in fT1D. The process of β cell destruction is extremely rapid in fT1D, and the insulin secretary capacity rarely recovers after the onset. The serum glycated albumin to glycated haemoglobin ratio is significantly higher in fT1D; a cut-off value of 3.2 for serum glycated albumin to glycated haemoglobin ratio yielded 97% sensitivity and 98% specificity for differentiating fT1D from type 2 diabetes. Fulminant type 1 diabetes is associated with pregnancy. This article also updates the diagnostic criteria for fT1D by the Japanese Diabetes Association in 2012.KEYWORDS enteroviruses, fulminant type 1 diabetes, human leukocyte antigen, immunity

show abstract

Clinical analysis of fulminant type 1 diabetes in China and comparison with a nationwide survey in Japan

Cited by 5 publications

References 9 publications

A follow-up study of fulminant type 1 diabetes mellitus

A follow-up study of fulminant type 1 diabetes mellitus

Identification of hsa_circRNA_100632 as a novel molecular biomarker for fulminant type 1 diabetes

Recent findings on fulminant type 1 diabetes

Contact Info

Product

Resources

About